Based on the Stoke Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for Stoke Therapeutics Inc is USD 25.17 over the next 12 months. Stoke Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Stoke Therapeutics Inc is Slightly Bearish, which is based on 5 positive signals and 7 negative signals. At the last closing, Stoke Therapeutics Inc’s stock price was USD 9.50. Stoke Therapeutics Inc’s stock price has changed by -1.35% over the past week, +3.04% over the past month and -35.42% over the last year.
No recent analyst target price found for Stoke Therapeutics Inc
No recent average analyst rating found for Stoke Therapeutics Inc
Company Overview Stoke Therapeutics Inc
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase I/II clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Read Less
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in devel...Read More
Frequently Asked Questions About Stoke Therapeutics Inc (STOK) Stock
Based on ratings from 5 analysts Stoke Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on STOK's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for STOK is USD 25.17 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 20.
STOK stock's Price/Earning ratio is 11.90.
Our analysis grades STOK stock's Price / Earning ratio at F. This means that STOK stock's Price/Earning ratio is above 61% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this STOK may be a overvalued for its sector.
The last closing price of STOK's stock was USD 9.50.
The most recent market capitalization for STOK is USD 0.53B.
Based on targets from 5 analysts, the average taret price for STOK is projected at USD 25.17 over the next 12 months.
This means that STOK's stock price may go up by +164.91% over the next 12 months.
We can't find any ETFs which contains Stoke Therapeutics Inc's stock.
As per our most recent records Stoke Therapeutics Inc has 128 Employees.
Stoke Therapeutics Inc's registered address is 45 Wiggins Avenue, Bedford, MA, United States, 01730.
You can get more information about it from Stoke Therapeutics Inc's website at https://www.stoketherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Stoke Therapeutics Inc (STOK) Stock
Based on ratings from 5 analysts Stoke Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 12 buy, sell and hold ratings.
Unfortunately we do not have enough data on STOK's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for STOK is USD 25.17 over the next 12 months. The maximum analyst target price is USD 35 while the minimum anlayst target price is USD 20.
STOK stock's Price/Earning ratio is 11.90.
Our analysis grades STOK stock's Price / Earning ratio at F. This means that STOK stock's Price/Earning ratio is above 61% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this STOK may be a overvalued for its sector.
The last closing price of STOK's stock was USD 9.50.
The most recent market capitalization for STOK is USD 0.53B.
Based on targets from 5 analysts, the average taret price for STOK is projected at USD 25.17 over the next 12 months.
This means that STOK's stock price may go up by +164.91% over the next 12 months.
We can't find any ETFs which contains Stoke Therapeutics Inc's stock.
As per our most recent records Stoke Therapeutics Inc has 128 Employees.
Stoke Therapeutics Inc's registered address is 45 Wiggins Avenue, Bedford, MA, United States, 01730.
You can get more information about it from Stoke Therapeutics Inc's website at https://www.stoketherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STOK !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
